Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

[News]

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics," held in Berlin, Germany, November 16-19.

More... (http://www.news-medical.net/news/20101119/Clinical-data-of-CU-201-CUDC-101-presented-at-EORTC-NCI-AACR-Symposium.aspx)